证券代码：603301 证券简称：振德医疗 公告编号：2025-003 振德医疗用品股份有限公司 第三届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）第三届董事会 第二十次会议于 2025 年 4 月 24 日在公司会议室以现场结合通讯方式 召开，会议通知已于 2025 年 4 月 14 日以传真、E-MAIL 和专人送达 等形式提交各董事。本次会议由公司董事长鲁建国先生主持，会议应 出席董事 9 名，实际出席董事 9 名，公司监事、高级管理人员列席了 本次会议，符合《公司法》和《公司章程》的有关规定，决议合法有 效。 会议审议议案后形成以下决议： 1、审议通过《公司 2024 年度董事会工作报告》，董事会同意将 本报告提交公司 2024 年年度股东大会审议。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、审议通过《公司 2024 年度总经理工作报告》。 本报告已经公司第三届董事会战略委员会第四次会议审议通过。 表决结果：同意 9 票，反对 ...

证券代码：603301 证券简称：振德医疗 公告编号：2025-005 3、在实施权益分派的股权登记日前公司本次利润分配股份基数 发生变动的，拟维持每股分配 0.65 元（含税）不变，相应调整分配 总额，并将另行公告具体调整情况。 4、公司不触及《上海证券交易所股票上市规则》第 9.8.1 条第 一款第（八）项规定的可能被实施其他风险警示的情形。 振德医疗用品股份有限公司 关于公司 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、每股分配金额：每股派发现金红利 0.65 元（含税）。 2、本次利润分配以实施权益分派股权登记日登记的总股本扣除 公司回购专户的股份数为分配基数，具体日期将在权益分派实施公告 中明确。 一、利润分配方案的具体内容 经天健会计师事务所（特殊普通合伙）审计，公司 2024 年度末 合并报表未分配利润为 3,377,815,618.11 元，母公司报表未分配利 润为 1,477,982,596.17 元。 （一）本次利润分配预案如下：公司拟以实施权益分派 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 1.4500 | 0.7400 | 95.95 | 2.8700 | | 每股净资产（元） | 21.18 | 20.14 | 5.16 | 20.8 | | 每股公积金(元) | 6.71 | 6.71 | 0 | 6.69 | | 每股未分配利润(元) | 12.68 | 11.80 | 7.46 | 12.60 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 42.64 | 41.27 | 3.32 | 61.38 | | 净利润(亿元) | 3.85 | 1.98 | 94.44 | 6.8 | | 净资产收益率(%) | 7.00 | 3.60 | 94.44 | 14.84 | 数据四舍五入，查看更多财务数据>> | 名称 持有数量(万股) | | 占总股本比例 (%) | 增减情况(万 股) | | --- | --- | --- ...

目 录 | 一、审计报告……………………………………………………… | 第 | 1—6 | 页 | | --- | --- | --- | --- | | 二、财务报表……………………………………………………… | 第 | 7—14 | 页 | | （一）合并资产负债表…………………………………………… | | 第 7 | 页 | | （二）母公司资产负债表………………………………………… | | 第 8 | 页 | | （三）合并利润表………………………………………………… | | 第 9 | 页 | | （四）母公司利润表………………………………………………第 | | 10 | 页 | | （五）合并现金流量表……………………………………………第 | | 11 | 页 | | （六）母公司现金流量表…………………………………………第 | | 12 | 页 | | （七）合并所有者权益变动表……………………………………第 | | 13 | 页 | | （八）母公司所有者权益变动表…………………………………第 | | 14 | 页 | | 第 15—109 页 | | --- | | 三、财务报表附注………… ...

天健审〔2025〕8310 号 振德医疗用品股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了振德医疗用品股份有限公司（以下简称振德医疗公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 目 录 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是振德 医疗公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，振德医疗公司于 2024 年 12 月 31 日按照《企业内部控制 ...

二、非经营性资金占用及其他关联资金往来情况汇总表…………第 3—3 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 本报告仅供振德医疗公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为振德医疗公司年度报告的必备文件，随同其他文件一起报送 并对外披露。 为了更好地理解振德医疗公司 2024 年度非经营性资金占用及其他关联资金 往来情况，汇总表应当与已审的财务报表一并阅读。 二、管理层的责任 振德医疗公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会 公告〔2022〕26 号）和《上海证券交易所上市公司自律监管指南第 2 号——业 务办理（2024 年 5 月修订）》（上证函〔2024〕1476 号）的规定编制汇总表， 并保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 第 1 页 共 3 页 三、注册会计师的责任 天健审〔2025〕8311 号 振德医疗用品 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 991,564,852.44, representing a 2.87% increase compared to CNY 963,887,437.65 in the same period last year[4] - Net profit attributable to shareholders decreased by 30.19% to CNY 51,241,871.64 from CNY 73,397,631.01 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 36.34% to CNY 47,555,148.75 compared to CNY 74,696,045.21 in the previous year[4] - Basic and diluted earnings per share decreased by 32.14% to CNY 0.19 from CNY 0.28 year-on-year[4] - Net profit for Q1 2025 was ¥52,407,784.36, a decrease of 30.3% from ¥75,230,110.17 in Q1 2024[18] - Earnings per share for Q1 2025 were ¥0.19, down from ¥0.28 in Q1 2024[18] - The company reported a total comprehensive income of ¥74,364,364.64 for Q1 2025, compared to ¥112,931,841.28 in Q1 2024, a decrease of 34%[18] Cash Flow - The net cash flow from operating activities was negative at CNY -27,769,957.87, a significant decline of 205.60% from CNY 26,297,173.49 in the same period last year[4] - Cash inflow from operating activities for Q1 2025 was $1,196,695,032.81, an increase of 14.2% compared to $1,048,332,483.77 in Q1 2024[22] - The total cash inflow from operating activities was $1,196,695,032.81, while total cash outflow was $1,224,464,990.68, resulting in a net cash flow of -$27,769,957.87 for Q1 2025[22] - Cash outflow for purchasing goods and services was $717,154,156.32 in Q1 2025, up from $641,089,503.20 in Q1 2024, reflecting a 11.9% increase[22] - Cash inflow from financing activities decreased to $740,000,000.00 in Q1 2025 from $1,127,760,000.00 in Q1 2024, a decline of 34.3%[23] - The ending cash and cash equivalents balance for Q1 2025 was $922,246,634.03, a decrease of 41.2% from $1,569,377,047.93 in Q1 2024[23] - The company reported a cash outflow of $134,087,464.68 for taxes in Q1 2025, significantly higher than $64,463,864.95 in Q1 2024, indicating a 107.5% increase[22] Assets and Liabilities - Total assets increased by 7.36% to CNY 8,134,455,327.52 from CNY 7,576,854,384.35 at the end of the previous year[5] - Total liabilities increased to CNY 3,073,006,079.04, with short-term borrowings rising significantly to CNY 706,935,455.19 from CNY 266,715,241.50, marking an increase of approximately 164.0%[13] - The total assets of the company reached CNY 8,134,455,327.52, up from CNY 7,576,854,384.35, which is an increase of about 7.3%[13] - The company's non-current assets totaled CNY 5,061,449,248.48, compared to CNY 4,927,035,342.48, reflecting a growth of approximately 2.7%[13] - Total liabilities increased to ¥2,163,686,458.58 in Q1 2025, compared to ¥1,680,456,463.01 in Q1 2024, reflecting a growth of 28.7%[14] - Total equity rose to ¥5,970,768,868.94 in Q1 2025, compared to ¥5,896,397,921.34 in Q1 2024, marking an increase of 1.3%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,690[9] - The company has not reported any significant changes in shareholder structure or participation in margin trading activities during the reporting period[11] Costs and Expenses - The company experienced increased costs due to exchange rate fluctuations, higher operational expenses from new overseas production facilities, and increased R&D investments[7] - Total operating costs for Q1 2025 were ¥932,157,374.02, up 7.1% from ¥870,157,936.80 in Q1 2024[17] - Research and development expenses for Q1 2025 were ¥33,484,212.15, up from ¥29,493,825.79 in Q1 2024, indicating a growth of 13.5%[17] Other Financial Metrics - The weighted average return on equity decreased by 0.46 percentage points to 0.90% from 1.36% year-on-year[4] - The company reported a total non-recurring gains and losses of CNY 3,686,722.89 for the period[7] - Other comprehensive income after tax for Q1 2025 was ¥21,956,580.28, down from ¥37,701,731.11 in Q1 2024[18] - Long-term borrowings increased to ¥385,900,927.80 in Q1 2025 from ¥283,106,001.32 in Q1 2024, reflecting a growth of 36.4%[14] - The company experienced a negative impact of -$678,206.74 from exchange rate fluctuations in Q1 2025, contrasting with a positive impact of $11,066,285.10 in Q1 2024[23]

Financial Performance - The company's operating revenue for 2024 reached ¥4,263,886,317.39, representing a 3.32% increase compared to ¥4,127,044,057.44 in 2023[23]. - The net profit attributable to shareholders for 2024 was ¥385,170,721.28, a significant increase of 94.14% from ¥198,399,010.76 in 2023[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥316,398,696.81, up 66.89% from ¥189,587,741.53 in 2023[23]. - The net cash flow from operating activities for 2024 was ¥461,142,986.68, a slight increase of 2.00% compared to ¥452,107,162.00 in 2023[23]. - The total assets at the end of 2024 amounted to ¥7,576,854,384.35, reflecting a 4.27% increase from ¥7,266,719,674.70 at the end of 2023[23]. - The net assets attributable to shareholders increased by 5.17% to ¥5,643,251,376.11 at the end of 2024, compared to ¥5,365,596,147.58 at the end of 2023[23]. - Basic earnings per share increased by 95.95% to CNY 1.45 in 2024 from CNY 0.74 in 2023[24]. - The weighted average return on equity rose by 3.4 percentage points to 7.00% in 2024 compared to 3.60% in 2023[24]. - The company achieved operating revenue of 4.264 billion yuan, a year-on-year increase of 3.32%, with core business revenue (excluding isolation protective products) growing by 15.80% to 4.104 billion yuan[34]. - The company reported a net cash flow from operating activities of CNY 301,624,869.98 in the fourth quarter of 2024[27]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of ¥6.50 per 10 shares (including tax), totaling approximately ¥173,109,144 (including tax) based on the adjusted share base[6]. - The cash dividend amount (including tax) was CNY 173,109,144, representing 44.94% of the net profit attributable to ordinary shareholders[184]. - Over the last three accounting years, the cumulative cash dividend amount (including tax) was CNY 705,752,664, with an average annual net profit of CNY 421,149,291.52, resulting in a cash dividend ratio of 167.58%[185]. Market and Business Strategy - The company aims to maintain steady growth in the healthcare sector, driven by policy support and technological innovation amid a complex market environment[33]. - The company plans to continue its dual-drive strategy focusing on both domestic and international markets to achieve its operational goals[33]. - The company is focused on enhancing its core competitive advantages through increased investment in innovation and product diversification in the low-value consumables sector[54]. - The company aims to improve the quality of life for patients through its diverse range of healthcare and personal care products[66]. - The company is committed to becoming a leading healthcare enterprise with a market value of over 10 billion yuan, focusing on medical and health sectors with certain international influence[132]. Research and Development - The company obtained 9 new Class II medical device registrations and 28 invention patents during the reporting period, totaling 105 invention patents and 136 Class II medical device registrations by the end of the reporting period[41]. - The company focused on innovation-driven strategies, enhancing R&D capabilities in high polymer materials and new antibacterial materials, with significant progress in product development[39]. - Research and development expenses totaled 135,489,953.88, representing 3.36% of total revenue, with a decrease of 2.49% compared to the previous year[88]. - The company plans to continue investing in R&D innovation and digital transformation to enhance operational efficiency and reduce costs[133]. Operational Efficiency and Digital Transformation - The company achieved significant improvements in operational efficiency through digital transformation and process optimization, enhancing employee productivity metrics[43]. - The integration of artificial intelligence and process automation has notably increased work efficiency and service quality, with the deployment of BPM management systems providing precise data support for decision-making[44]. - The company plans to enhance its supply chain efficiency, aiming for a 15% reduction in operational costs by the end of the year[158]. - The company will enhance its digital transformation by integrating AI and robotic process automation to improve internal efficiency and decision-making capabilities[140]. Corporate Governance and Compliance - The company adheres to legal regulations and optimizes its corporate governance structure, ensuring fair treatment of all shareholders[150]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards[151]. - The company emphasizes strict adherence to information disclosure obligations, ensuring transparency and fairness in its communications[5]. - The company has established a robust investor relations management system, facilitating communication through various channels[5]. Environmental Responsibility - The company invested 11.78 million yuan in environmental protection during the reporting period[196]. - The company has implemented various environmental management measures, including ISO14001 and ISO45001 certifications, to enhance its green development initiatives[198]. - The company is committed to promoting green development and has adopted measures to optimize energy use and reduce carbon emissions[199]. Market Trends and Opportunities - The global medical device market reached $582.6 billion in 2023, with a year-on-year growth of 5.40%, and is projected to grow to $617.6 billion in 2024[48]. - China's medical device market size reached ¥1,032.8 billion in 2023, growing by 5.07% year-on-year, positioning it as the second-largest market globally[50]. - The company is exploring market expansion opportunities in both domestic and international markets for its healthcare products[67]. Employee Engagement and Development - The total number of employees in the parent company and major subsidiaries is 7,807, with 4,826 in production, 638 in sales, and 673 in technical roles[174]. - The company has implemented a talent development system focusing on core competencies and clear career paths for employees[177]. - The company has established a multi-level incentive policy to enhance team collaboration and performance, focusing on a diverse performance evaluation system for different positions[175].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhend Medical, which closed at 20.72 yuan with a PE ratio of 26.89 times, significantly lower than the industry average of 45.71 times [1][2] - Zhend Medical's total market capitalization is reported at 5.521 billion yuan, ranking 66th in the medical device industry based on PE ratio [1][2] - As of the third quarter of 2024, 181 institutions hold shares in Zhend Medical, with a total holding of 20.3871 million shares valued at 448 million yuan [1] Group 2 - The main business of Zhend Medical includes the production, research, and sales of medical dressings, with key products in wound care, surgical infection control, and pressure treatment [1] - The latest financial results for the third quarter of 2024 show Zhend Medical achieved operating revenue of 3.125 billion yuan, a year-on-year decrease of 2.61%, while net profit was 307 million yuan, an increase of 2.31%, with a gross profit margin of 34.84% [1]

最新一期业绩显示，2024年三季报，公司实现营业收入31.25亿元，同比-2.61%；净利润3.07亿元，同比 2.31%，销售毛利率34.84%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)64振德医疗28.7029.711.0658.94亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11328.30亿10中红医疗-54.40-37.010.8648.44 亿11天智航-46.58-46.584.8657.34亿 来源：金融界 从行业市盈率排名来看， ...